Literature DB >> 11905817

Epstein-Barr virus: exploiting the immune system.

D A Thorley-Lawson1.   

Abstract

In vitro, Epstein-Barr virus (EBV) will infect any resting B cell, driving it out of the resting state to become an activated proliferating lymphoblast. Paradoxically, EBV persists in vivo in a quiescent state in resting memory B cells that circulate in the peripheral blood. How does the virus get there, and with such specificity for the memory compartment? An explanation comes from the idea that two genes encoded by the virus--LMP1 and LMP2A--allow EBV to exploit the normal pathways of B-cell differentiation so that the EBV-infected B blast can become a resting memory cell.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11905817     DOI: 10.1038/35095584

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  340 in total

1.  B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression.

Authors:  Barbro Ehlin-Henriksson; John Gordon; George Klein
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

2.  Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during B-lymphocyte development.

Authors:  Toni Portis; Richard Longnecker
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Immature and transitional B cells are latency reservoirs for a gammaherpesvirus.

Authors:  Carrie B Coleman; Michael S Nealy; Scott A Tibbetts
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

4.  Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency.

Authors:  David J Hughes; Elessa M Marendy; Carol A Dickerson; Kristen D Yetming; Clare E Sample; Jeffery T Sample
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

5.  EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.

Authors:  Robert E White; Patrick C Rämer; Kikkeri N Naresh; Sonja Meixlsperger; Laurie Pinaud; Cliona Rooney; Barbara Savoldo; Rita Coutinho; Csaba Bödör; John Gribben; Hazem A Ibrahim; Mark Bower; Jamie P Nourse; Maher K Gandhi; Jaap Middeldorp; Fathima Z Cader; Paul Murray; Christian Münz; Martin J Allday
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

6.  Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus.

Authors:  Takashi Nakayama; Kunio Hieshima; Daisuke Nagakubo; Emiko Sato; Masahiro Nakayama; Keisei Kawa; Osamu Yoshie
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

7.  Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.

Authors:  Donna Hochberg; Jaap M Middeldorp; Michelle Catalina; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

Review 8.  Latency in human immunodeficiency virus type 1 infection: no easy answers.

Authors:  Deborah Persaud; Yan Zhou; Janet M Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  Maintenance of gammaherpesvirus latency requires viral cyclin in the absence of B lymphocytes.

Authors:  Linda F van Dyk; Herbert W Virgin; Samuel H Speck
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

10.  Postinternalization inhibition of adenovirus gene expression and infectious virus production in human T-cell lines.

Authors:  Adrienne L McNees; Jeff A Mahr; David Ornelles; Linda R Gooding
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.